Division of Dermatology, Department of Medicine, University of California, San Diego, San Diego, California 92121, USA.
J Invest Dermatol. 2011 Feb;131(2):401-9. doi: 10.1038/jid.2010.319. Epub 2010 Nov 18.
The need for a new anti-Staphylococcus aureus therapy that can effectively cripple bacterial infection, neutralize secretory virulence factors, and lower the risk of creating bacterial resistance is undisputed. Here, we propose what is, to our knowledge, a previously unreported infectious mechanism by which S. aureus may commandeer Propionibacterium acnes, a key member of the human skin microbiome, to spread its invasion and highlight two secretory virulence factors (S. aureus β-hemolysin and P. acnes CAMP (Christie, Atkins, Munch-Peterson) factor) as potential molecular targets for immunotherapy against S. aureus infection. Our data demonstrate that the hemolysis and cytolysis by S. aureus were noticeably augmented when S. aureus was grown with P. acnes. The augmentation was significantly abrogated when the P. acnes CAMP factor was neutralized or β-hemolysin of S. aureus was mutated. In addition, the hemolysis and cytolysis of recombinant β-hemolysin were markedly enhanced by recombinant CAMP factor. Furthermore, P. acnes exacerbated S. aureus-induced skin lesions in vivo. The combination of CAMP factor neutralization and β-hemolysin immunization cooperatively suppressed the skin lesions caused by coinfection of P. acnes and S. aureus. These observations suggest a previously unreported immunotherapy targeting the interaction of S. aureus with a skin commensal.
需要一种新的抗金黄色葡萄球菌疗法,这种疗法能够有效削弱细菌感染、中和分泌性毒力因子,并降低产生细菌耐药性的风险,这一点是毋庸置疑的。在这里,我们提出了一种据我们所知,以前尚未报道过的金黄色葡萄球菌感染机制,该机制可能利用痤疮丙酸杆菌(一种人类皮肤微生物组的关键成员)来传播其侵袭,并强调了两种分泌性毒力因子(金黄色葡萄球菌β-溶血性素和痤疮丙酸杆菌 CAMP(Christie、Atkins、Munch-Peterson)因子)作为针对金黄色葡萄球菌感染的免疫疗法的潜在分子靶标。我们的数据表明,当金黄色葡萄球菌与痤疮丙酸杆菌共同培养时,金黄色葡萄球菌的溶血和细胞溶解作用明显增强。当中和痤疮丙酸杆菌 CAMP 因子或突变金黄色葡萄球菌β-溶血性素时,这种增强作用显著被阻断。此外,重组 CAMP 因子明显增强了重组β-溶血性素的溶血和细胞溶解作用。此外,痤疮丙酸杆菌在体内加剧了金黄色葡萄球菌引起的皮肤损伤。CAMP 因子中和和β-溶血性素免疫联合抑制了痤疮丙酸杆菌和金黄色葡萄球菌共同感染引起的皮肤损伤。这些观察结果表明,针对金黄色葡萄球菌与皮肤共生菌相互作用的免疫疗法是以前未曾报道过的。